Pharmacologic Therapy for Eating Disorders

Introduction to Eating Disorder Treatment

• The American Psychiatric Association recommends fluoxetine 60 mg daily as the primary pharmacologic agent for bulimia nervosa, while for anorexia nervosa, psychotherapy remains the primary treatment 1, 2

Bulimia Nervosa Treatment

• Fluoxetine at 60 mg daily is the only medication with strong evidence and FDA approval for bulimia nervosa, and is statistically superior to placebo in reducing binge-eating and purging frequency 1, 2, 3
• The American Psychiatric Association suggests initiating fluoxetine alongside cognitive-behavioral therapy (CBT), or if minimal or no response to psychotherapy alone by 6 weeks of treatment 1, 2

Anorexia Nervosa Treatment

• The American Psychiatric Association states that no medications are approved for anorexia nervosa, and current evidence does not support routine pharmacologic treatment for weight restoration 1, 2
• Eating disorder-focused psychotherapy combined with nutritional rehabilitation and weight restoration is the cornerstone of anorexia nervosa treatment 1, 2

Special Populations

• For adolescents and emerging adults with bulimia nervosa, family-based treatment is suggested, while for anorexia nervosa, family-based treatment with caregiver involvement is strongly recommended 1, 2

Critical Evaluation Requirements

• The American Psychiatric Association recommends mandatory initial assessment including vital signs, complete blood count, comprehensive metabolic panel, electrocardiogram, and quantification of eating behaviors 1, 2

Common Pitfalls to Avoid

• The American Psychiatric Association advises against using standard antidepressant doses of fluoxetine (20 mg) for bulimia nervosa, and instead recommends 60 mg daily 3
• Oral contraceptives should not be used to "treat" amenorrhea in anorexia nervosa, as they create false reassurance with withdrawal bleeding but do not restore spontaneous menses and may compromise bone health 4

Multidisciplinary Team Requirements

• The American Psychiatric Association emphasizes that all eating disorder treatment requires coordination among medical, psychiatric, psychological, and nutritional expertise 1, 2

Alternative and Emerging Approaches

• Guided computer-based interventions and videoconferencing show promise for bulimia nervosa, particularly for overcoming barriers like shame, stigma, and provider shortages 5, 6, 3
• Lisdexamfetamine has the strongest evidence for binge-eating disorder, but is not approved in Germany for this indication 7, 1, 2

Treatment of Bulimia Nervosa with Fluoxetine Intolerance

Introduction to Alternative Treatments

• The American Psychiatric Association recommends that patients with bulimia nervosa who do not tolerate fluoxetine should be treated with an alternative selective serotonin reuptake inhibitor (SSRI), such as sertralina (100 mg/day) or citalopram, based on moderate-quality evidence 8.

Pharmacological Options for Second-Line Treatment

• The American Journal of Psychiatry suggests that sertralina 100 mg/day for 12 weeks can reduce the frequency of compulsive eating and purging episodes, with a statistically significant difference compared to placebo, in patients with bulimia nervosa 8.
• The National Institute of Mental Health guidelines indicate that citalopram may be particularly useful in patients with bulimia nervosa and prominent depressive symptoms, with a greater reduction in depressive symptoms compared to fluoxetine 9.

Decision-Making Algorithm

• The American Psychiatric Association recommends assessing the type of intolerance to fluoxetine and considering alternative SSRI treatment, such as sertralina 100 mg/day or citalopram, based on moderate-quality evidence 8, 9.
• The Nature Reviews Gastroenterology and Hepatology guidelines suggest that patients with bulimia nervosa should continue to receive cognitive-behavioral therapy (CBT) focused on eating disorders, in addition to alternative SSRI treatment, to improve treatment outcomes 8, 9.

Important Considerations

• The American Journal of Psychiatry guidelines recommend that patients with bulimia nervosa should be monitored for response to treatment every 6-12 weeks, with assessment of reduction in frequency of compulsive eating and purging episodes, and quantification of eating behaviors weekly 8.
• The American Psychiatric Association suggests that vital signs, including orthostatic blood pressure, complete blood count, comprehensive metabolic panel, and electrocardiogram (especially in patients with severe purging), should be evaluated before initiating alternative medication 8, 9.

Evidence‑Based Recommendations for Anorexia Nervosa Management (American Psychiatric Association, 2023)

First‑Line Psychotherapeutic and Nutritional Interventions

• Psychotherapy focused on eating‑disorder pathology is the cornerstone treatment for adults with anorexia nervosa, targeting normalization of eating behaviors, weight restoration, and reduction of fear of weight gain and body‑image disturbance. 10, 11
• For adolescents and young adults with a caregiver present, family‑based treatment is the recommended approach, incorporating caregiver education to normalize eating and promote weight restoration. 10, 11
• Individualized nutritional rehabilitation with weekly weight‑gain goals is a mandatory component of first‑line care. 10, 11
• Care should be delivered by a coordinated multidisciplinary team (medical, psychiatric, psychological, nutritional). 10, 11

Pre‑Medication Safety Assessments

• An electrocardiogram must be obtained before any psychotropic medication because QTc prolongation is common in restrictive anorexia nervosa. 10, 11
• Baseline comprehensive metabolic panel, including electrolytes, is required prior to medication initiation. 10, 11
• Baseline vital‑sign assessment, including orthostatic blood‑pressure measurement, must be recorded before starting medication. 10, 11
• Baseline complete blood count should be obtained before any pharmacologic intervention. 10, 11

Monitoring During Pharmacologic Adjuncts

• When a medication with QT‑prolonging potential is prescribed, repeat ECG monitoring is advised. 10, 11

Common Pitfalls to Avoid

• Initiating psychotropic medication without prior cardiac evaluation is discouraged, as both anorexia nervosa and certain psychiatric drugs can prolong the QTc interval. 10, 11

Pharmacologic Adjunct Dosing Recommendations for Anorexia Nervosa

Olanzapine (First‑Line Adjunct)

• Initiate olanzapine at 5 mg once daily as the starting dose for patients receiving adjunctive pharmacotherapy alongside psychotherapy and nutritional rehabilitation. 12, 13, 14

Antidepressant Options for Comorbid Mood Symptoms

• Mirtazapine may be used when depressive symptoms are prominent; prescribe 7.5 mg to 30 mg at bedtime, which also provides appetite‑stimulating effects. 12, 13, 14

Appetite‑Stimulating Agents (Limited Evidence in Anorexia Nervosa)

• Megestrol acetate has been referenced in oncology guidelines for cancer‑related anorexia; dosing ranges from 400 mg to 800 mg per day. 12, 13, 14
• Dexamethasone is similarly cited in oncology contexts; recommended dose is 2 mg to 8 mg per day. 12, 13, 14

Evidence on Pharmacologic Adjuncts and Contraindications in Anorexia Nervosa

Ineffective Augmentation in Related Psychiatric Conditions

Inapplicability of Cancer‑Related Appetite Stimulants to Anorexia Nervosa

Pharmacologic Recommendations for Anxiety in Patients with Eating Disorders

First‑Line SSRIs for Comorbid Anxiety

• Selective serotonin reuptake inhibitors (SSRIs) are recommended as the first‑line pharmacologic treatment for adults who have both an anxiety disorder and an eating disorder; the specific SSRI choice and dose should be tailored to the type of eating disorder present. 19

SSRIs for Anxiety in Anorexia Nervosa

• In patients with anorexia nervosa who experience severe anxiety that interferes with treatment engagement, fluoxetine, sertraline, or escitalopram may be prescribed only after a cardiac safety evaluation (e.g., ECG) to mitigate the risk of QTc prolongation. [19][20]

Recommended SSRIs for Generalized Anxiety Across Eating‑Disorder Subtypes

• Fluoxetine, paroxetine, and escitalopram are the SSRIs with the most established safety profiles for treating generalized anxiety in individuals with eating disorders. [19][20]
• When SSRIs are insufficient or not tolerated, venlafaxine (an SNRI) is suggested as an alternative option. 19